

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

**UNAUDITED FINANCIAL INFORMATION OF
CSPC INNOVATION PHARMACEUTICAL CO., LTD.
FOR THE SIX MONTHS ENDED 30 JUNE 2025**

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), a subsidiary of CSPC Pharmaceutical Group Limited (the “**Company**”) listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765), has on 15 August 2025 published its unaudited interim report for the six months ended 30 June 2025 (the “**2025 Interim Report**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>. CSPC Innovation’s financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the “**Appendices**”) is the principal financial data of CSPC Innovation extracted from the 2025 Interim Report prepared in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and potential investors of the Company are reminded that the financial information of CSPC Innovation in the 2025 Interim Report and in the Appendices are unaudited consolidated financial information of CSPC Innovation for the six months ended 30 June 2025, rather than that of the Company. They should exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 15 August 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

APPENDIX I

KEY ACCOUNTING DATA AND FINANCIAL INDICATORS

Currency: RMB

	Current reporting period	Corresponding period of last year	Increase/decrease in the current reporting period compared with the corresponding period of last year
Operating revenue (Yuan)	1,049,557,677.74	971,860,199.72	7.99%
Net profit attributable to shareholders of the listed company (Yuan)	-2,746,143.58	137,027,524.09	-102.00%
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (Yuan)	-41,144,138.18	134,482,142.06	-130.59%
Net cash flows generated from operating activities (Yuan)	-151,806,119.45	-941,443,278.00	83.88%
Basic earnings per share (Yuan/share)	-0.0020	0.0976	-102.05%
Diluted earnings per share (Yuan/share)	-0.0020	0.0976	-102.05%
Weighted average return on net assets	-0.07%	2.64%	-2.71%
	End of current reporting period	End of last year	Increase/decrease at the end of the current reporting period compared with the end of last year
Total assets (Yuan)	6,165,171,574.72	6,022,115,755.32	2.38%
Net assets attributable to shareholders of the listed company (Yuan)	3,706,913,849.96	3,730,544,275.59	-0.63%

APPENDIX II

NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS

Unit: Yuan Currency: RMB

Items	Amount
Gains/losses on disposal of non-current assets (including the portion offset with the provision for impairment of assets)	1,788,518.34
Government grants recognised in profit or loss for the current period (excluding those closely related to the company's normal operating business, complied with national policies and regulations, granted according to established standards, and continuously affecting the company's gain/loss)	67,695,526.58
Profit or loss from changes in fair value of financial assets and financial liabilities and profit or loss from disposal of financial assets and financial liabilities held by non-financial enterprises, other than effective hedging activities related to normal business operations of the company	3,682,388.23
Non-operating income and expenses other than the items above	-1,849,953.49
Less: Impact of income tax	652,266.30
Impact of minority interests (after tax)	32,266,218.76
Total	38,397,994.60

APPENDIX III

SIGNIFICANT CHANGES IN ASSETS COMPONENTS

Unit: Yuan Currency: RMB

	End of current reporting period		End of last year		Increase/ decrease in proportion	Description of significant changes
	Amount	Proportion to total asset	Amount	Proportion to total asset		
Cash and bank balances	815,530,257.95	13.23%	872,081,872.91	14.48%	-1.25%	No significant changes.
Trade receivables	474,024,396.16	7.69%	314,097,126.88	5.22%	2.47%	Mainly due to increase in operating revenue, with accounts receivable from credit sales within the credit period yet to be collected.
Inventories	433,528,007.41	7.03%	398,668,570.98	6.62%	0.41%	No significant changes.
Long-term equity investments	287,188,269.57	4.66%	264,448,153.62	4.39%	0.27%	No significant changes.
Fixed assets	1,943,126,168.59	31.52%	2,046,598,550.77	33.98%	-2.46%	Mainly due to depreciation of fixed assets provided by the Company.
Construction in progress	746,390,374.81	12.11%	620,225,532.01	10.30%	1.81%	Mainly due to the accelerated progress of the projects of Megalith Biopharmaceutical.
Right-of-use assets	714,198.34	0.01%	1,328,072.18	0.02%	-0.01%	No significant changes.
Contract liabilities	27,679,762.52	0.45%	18,683,904.44	0.31%	0.14%	Mainly due to the increase in receipts in advance.